GlassScriptPhysician profile
Suresh Nukala
NPI 1578643037
$2,515.49
in general payments reported to CMS, 2019-2025
29 companies · $410 in 2025
The $410 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $102 · 2021: $389 · 2022: $554 · 2023: $346 · 2024: $327 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.38 |
| Education | $249.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $480.15 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $310.80 | 2019-2024 | Farxiga, Enhertu, Lynparza |
| Novocure Gmbh | $250.00 | 2022 | |
| Abbvie INC. | $233.54 | 2021-2025 | |
| Gilead Sciences, INC. | $128.26 | 2021-2025 | Trodelvy |
| Akebia Therapeutics INC | $123.66 | 2025 | Vafseo |
| Alnylam Pharmaceuticals INC. | $123.66 | 2024 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $105.45 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $104.94 | 2021-2025 | Keytruda, Lynparza |
| Alexion Pharmaceuticals, INC. | $92.68 | 2024-2025 | Ultomiris |
| Amgen INC. | $70.87 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $65.62 | 2021-2022 | |
| Seagen INC. | $65.34 | 2022 | |
| Eisai INC. | $51.67 | 2019-2020 | |
| Pfizer INC. | $45.69 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Bct, INC. | $36.36 | 2019 | |
| Genzyme Corporation | $35.00 | 2019-2025 | |
| Celgene Corporation | $32.00 | 2021-2023 | Reblozyl |
| Kite Pharma, INC. | $28.51 | 2022-2023 | |
| Novo Nordisk INC | $20.50 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.87 | 2023 | |
| Adc Therapeutics America, INC. | $17.45 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.34 | 2021 | |
| Immunomedics, INC. | $16.74 | 2020 | |
| Genentech USA, INC. | $15.64 | 2021 | |
| Sobi, INC | $13.15 | 2022 | |
| Cti Biopharma Corp. | $12.60 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Nukala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.